Among the most studied “neuro” research peptides are three compounds with an unusual origin story: Semax, Selank, and DSIP. The first two emerged from Soviet and Russian academic pharmacology, while DSIP traces back to mid-twentieth-century sleep neuroscience in Switzerland. Each is a short peptide that appears to interact with signaling systems in the central nervous system — neurotrophic factors, GABAergic and serotonergic tone, and the regulation of sleep-related states. This guide explains what the preclinical and laboratory literature actually reports about these neuropeptides, where they came from, and how researchers categorize them. Everything here is for research use only and not for human consumption.
What “neuropeptide” means in a research context
Neuropeptides are short chains of amino acids that act as signaling molecules in the nervous system. Unlike classical small-molecule neurotransmitters, they tend to modulate — turning the gain up or down on existing circuits rather than acting as simple on/off switches. In the laboratory, this modulatory quality is exactly why they draw interest: researchers can probe how a defined sequence influences a specific pathway.
The peptides covered here — Semax, Selank, and DSIP — are studied as regulatory peptides, a term Russian pharmacology has used for decades to describe endogenous-like compounds that fine-tune neural and neuroendocrine function. Several were designed as stabilized analogs of naturally occurring fragments, which is a recurring theme in this category.
These compounds sit within our broader specialty compounds category, alongside other sequences studied for niche signaling pathways rather than the metabolic or repair-focused families.
Semax: a fragment of ACTH with a Russian research heritage
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4–10) region, with a Pro-Gly-Pro tail added to slow enzymatic breakdown. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and much of its literature is published in Russian-language and translated neuropharmacology journals.
Proposed mechanisms in the literature
The most consistently reported finding in animal and cell studies is that Semax appears to influence expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB. BDNF is a central player in neuronal survival and synaptic plasticity, so a peptide that modulates it is naturally of interest to researchers studying neuroprotection models.
- Reported up-regulation of BDNF/TrkB signaling in rodent hippocampal tissue (preclinical)
- Modulation of dopaminergic and serotonergic systems in animal models
- Antioxidant and anti-inflammatory effects observed in cerebral ischemia models in rats (preclinical)
- Notably, the ACTH(4–10) fragment used lacks the classic corticotropic (steroidogenic) activity of the parent hormone
Because the ACTH fragment was selected to retain neurotropic signaling while shedding hormonal activity, Semax is often described in the literature as a neuropeptide rather than a hormone analog — an important distinction for researchers designing controls.
Selank: an analog of tuftsin studied for anxiolytic pathways
Selank comes from the same Russian research lineage. It is a synthetic heptapeptide based on tuftsin, an endogenous immunomodulatory tetrapeptide, again extended with a stabilizing Pro-Gly-Pro sequence to resist degradation. Where Semax literature centers on neurotrophic and cognitive-model endpoints, Selank research focuses heavily on anxiety-related and GABAergic pathways in animals.
What preclinical studies report
- Modulation of the GABAergic system in rodent models, the basis for its study as an anxiolytic-class peptide (preclinical)
- Reported influence on the expression and metabolism of brain monoamines, including serotonin
- Effects on enkephalin-degrading enzymes, which may prolong endogenous peptide signaling (in-vitro/animal)
- Immunomodulatory activity inherited from its tuftsin parent, including effects on cytokine balance in some models
Selank is frequently paired with Selank-vs-Semax comparisons in the literature because the two share an origin, a stabilization strategy, and a delivery format (both are commonly studied as intranasal solutions in animal work), yet target distinct primary systems — neurotrophic for Semax, GABAergic/anxiolytic for Selank.
DSIP: delta sleep-inducing peptide and the sleep literature
DSIP — Delta Sleep-Inducing Peptide — has an entirely different pedigree. It was first isolated in the 1970s by Schoenenberger and Monnier in Switzerland from the cerebral venous blood of rabbits during electrically induced sleep. Its name comes from the observation that infusing it appeared to promote delta-wave (slow-wave) EEG activity in early animal experiments.
A peptide that resists easy classification
DSIP is one of the more enigmatic neuropeptides. Despite its name, the sleep-promoting effect has been inconsistent across studies, and decades of research have described a surprisingly broad range of reported activities — which is itself a reason it remains a research subject rather than a settled story.
- Originally characterized by association with delta-wave sleep in animal EEG studies (preclinical)
- Reported interactions with circadian and neuroendocrine regulation in animal models
- Studied for possible roles in stress response and thermoregulation in rodents
- Found endogenously in tissue, but its precise physiological receptor and pathway remain incompletely defined in the literature
Side-by-side: Semax vs Selank vs DSIP
The table below summarizes how the research literature distinguishes these three neuropeptides. All entries describe preclinical and laboratory findings only.
| Peptide | Origin / parent | Primary studied system | Reported research focus | Class |
|---|---|---|---|---|
| Semax | ACTH(4–10) fragment + Pro-Gly-Pro (Russia) | Neurotrophic (BDNF/TrkB), monoamines | Neuroprotection & cognition models | Regulatory neuropeptide |
| Selank | Tuftsin analog + Pro-Gly-Pro (Russia) | GABAergic, serotonergic, immune | Anxiolytic-pathway & immunomodulation models | Regulatory neuropeptide |
| DSIP | Isolated from sleep-state blood (Switzerland, 1970s) | Sleep/EEG, neuroendocrine, circadian | Slow-wave sleep & stress-response models | Endogenous sleep-associated peptide |
A practical note for the bench: Semax and Selank share a deliberate design strategy (a stabilized fragment of a larger molecule), while DSIP is a naturally isolated sequence whose function is still being mapped. That difference shapes how each shows up in study designs.
Handling, stability, and verification
Short neuropeptides are typically supplied lyophilized (freeze-dried) and reconstituted with bacteriostatic or sterile water for laboratory work. Like most peptides, they are sensitive to repeated freeze-thaw cycles, light, and prolonged time at room temperature once in solution.
- Store the lyophilized powder cold and protected from light until use.
- Reconstitute per your protocol and record the concentration — see our reconstitution and storage guide.
- Aliquot to minimize freeze-thaw cycles on the working solution.
- Confirm identity and purity against the lot COA before any experiment.
Purity especially matters for neuro work, where small contaminants can confound sensitive behavioral or electrophysiological readouts. Our explainer on peptide purity covers how to interpret HPLC and mass-spec data on a certificate.
Where these fit in the broader peptide landscape
Neuro and nootropic research peptides occupy a distinct corner of the field. Unlike the growth-hormone-axis or metabolic GLP-1-class peptides, they are studied for central-nervous-system signaling rather than systemic endocrine or metabolic endpoints. That makes them a natural complement to other specialty peptides in a research catalog.
For investigators building a neuro-focused panel, the three covered here represent three different mechanistic anchors — neurotrophic (Semax), GABAergic/anxiolytic (Selank), and sleep/neuroendocrine (DSIP) — which is part of why they are so often studied together.
Common questions
Are Semax, Selank, and DSIP approved for human use?
No. These are research compounds sold for research use only and not for human consumption. They are not FDA-approved drugs in the United States, and the literature discussed here is preclinical (in-vitro and animal) or early clinical research. They should be handled only in appropriate laboratory settings.
Why are Semax and Selank so often grouped together?
They share an origin (Russian academic neuropharmacology), a design strategy (a peptide fragment stabilized with a Pro-Gly-Pro tail to resist enzymatic degradation), and a common research delivery format in animal studies. Mechanistically, however, the literature points them at different systems — Semax toward neurotrophic BDNF/TrkB signaling and Selank toward GABAergic and anxiolytic pathways.
What is the actual fragment Semax is derived from?
Semax is based on the ACTH(4–10) region of adrenocorticotropic hormone, plus an added Pro-Gly-Pro sequence. Importantly, this fragment was selected to retain neurotropic activity while lacking the steroidogenic (corticotropic) activity of the full hormone, which is why it is classified as a neuropeptide rather than a hormone analog.
Does DSIP reliably induce sleep in studies?
Not consistently. Although it was named for its association with delta-wave sleep in early animal EEG experiments, subsequent research has reported variable and sometimes contradictory effects across species and conditions. Its precise receptor and physiological pathway remain incompletely defined, which is part of why it is still an active research subject.
How should these neuropeptides be stored for research?
They are typically supplied lyophilized and should be kept cold and protected from light until reconstitution. Once in solution they are sensitive to freeze-thaw cycles, light, and time at room temperature, so aliquoting is recommended. Always confirm identity and purity against the lot Certificate of Analysis before use.
Related research reading
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977. https://www.ncbi.nlm.nih.gov/pubmed/267917
- Dolotov OV, et al. Semax, an analog of ACTH(4-10), increases BDNF and TrkB expression in the rat hippocampus. Preclinical neuropharmacology literature. https://pubmed.ncbi.nlm.nih.gov/
- PubChem Compound Summary: Selank (tuftsin analog peptide). National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/
- National Center for Biotechnology Information (NCBI/NIH), PubMed neuropeptide literature database. https://pubmed.ncbi.nlm.nih.gov/
Banger Labs supplies materials for laboratory and research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.
Shop research peptides
Research-grade, ≥ 99% HPLC standard, COA per batch:
- GHK-Cu Research Overview: Copper Peptide Mechanisms & Forms →
- GLP-1 Class Research Peptides Explained: Incretin Biology, Single vs Dual vs Triple Agonists →
- Peptide Mechanisms of Action: How the Major Research Classes Work →
Browse the full Research Library →
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.